摘要
目的:探讨人参皂苷Rg3联合西药治疗对肺癌患者术后辅助治疗的临床效果。方法:选择我院2010年3月—2013年2月收治的100例原发性肺癌术后患者作为研究对象,其中,对照组50例患者采用常规化疗治疗,而观察组50例患者采用人参皂苷Rg3联合西药进行治疗,比较两组患者的治疗效果。结果:治疗后,观察组白细胞减少患者有31例,占62.0%,明显低于对照组患者(P<0.05),提示了人参皂苷Rg3能够有效保护机体的造血功能,降低化疗中的不良反应。而且观察组患者的细胞免疫指标CD4/CD8比值、NK细胞的阳性率均较对照组患者出现了明显改善,组间差异具有明显统计学意义(P<0.05)。结论:人参皂苷Rg3联合西药化疗对肺癌的术后辅助治疗中具有较佳效果,可以明显降低化疗引起的血液毒副作用,有利于患者的预后,值得临床应用。
Objective： To investigate the clinical effect of ginsenoside Rg3 combined with Western medicine for the treatment of patients with lung cancer. Methods ： 100 cases of primary lung cancer patients were taken as research subjects. The control group （50 patients） was treated with conventional chemotherapy treatment and observation group （50 patients） with ginsenosides Rg3 combined with Western medicine treatment. Resuhs：After treatment, the observation group had 31 cases with neutropenia, accounting for 62.0%. It was significantly lower than that of the control patients （P〈0.05）, suggesting that ginsenosides Rg3 can effectively protect the body＇s hematopoietic fnnction, reduce the adverse effects of chemotherapy. And immune parameters of CD4/CD8 cells were observed in patients. The positive rate of NK cells showed a significant improvement in the patients compared with that of the control group and the difference was statistically significant （ P〈0.05 ） between groups. Conclusion ： Ginsenoside Rg3 combined with Western adjuvant chemotherapy in the treatment of lung cancer has better results, and it is worthy of clinical armlication.
出处
《辽宁中医药大学学报》
CAS
2014年第5期199-201,共3页
Journal of Liaoning University of Traditional Chinese Medicine
关键词
人参皂苷RG3
肺癌
化疗
ginsenoside Rg3
lung carcinoma
chemotherapy
